Evidence map›Paper›PMID 30245685›Full record

ArticleFrontiers in immunology2018

Thymopoiesis in Pre- and Post-Hematopoietic Stem Cell Transplantation.

Luis Klaus A da Rocha, Samar Freschi de Barros, Francine Bandeira, Alexia Bollini, Lucia Helena de A Testa, Anderson João Simione, Marina de O E Souza, Lilian P Zanetti, Leila Cibele S de Oliveira, Ana Claúdia F Dos Santos and 5 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Luis Klaus A da RochaLaboratory of Immunology, Heart Institute (InCor), Clinical Hospital, University of São Paulo, São Paulo, Brazil.
Samar Freschi de BarrosLaboratory of Immunology, Heart Institute (InCor), Clinical Hospital, University of São Paulo, São Paulo, Brazil.
Francine BandeiraHematopoietic Stem Cell Transplantation Sector, Amaral Carvalho Hospital, Jaú, Brazil.
Alexia BolliniHematopoietic Stem Cell Transplantation Sector, Amaral Carvalho Hospital, Jaú, Brazil.
Lucia Helena de A TestaHematopoietic Stem Cell Transplantation Sector, Amaral Carvalho Hospital, Jaú, Brazil.
Anderson João SimioneHematopoietic Stem Cell Transplantation Sector, Amaral Carvalho Hospital, Jaú, Brazil.
Marina de O E SouzaHematopoietic Stem Cell Transplantation Sector, Amaral Carvalho Hospital, Jaú, Brazil.
Lilian P ZanettiHematopoietic Stem Cell Transplantation Sector, Amaral Carvalho Hospital, Jaú, Brazil.
Leila Cibele S de OliveiraHematopoietic Stem Cell Transplantation Sector, Amaral Carvalho Hospital, Jaú, Brazil.
Ana Claúdia F Dos SantosHematopoietic Stem Cell Transplantation Sector, Amaral Carvalho Hospital, Jaú, Brazil.
Mair Pedro de SouzaHematopoietic Stem Cell Transplantation Sector, Amaral Carvalho Hospital, Jaú, Brazil.
Vergílio Antônio R ColturadoHematopoietic Stem Cell Transplantation Sector, Amaral Carvalho Hospital, Jaú, Brazil.
Jorge KalilLaboratory of Immunology, Heart Institute (InCor), Clinical Hospital, University of São Paulo, São Paulo, Brazil.
Clarisse M MachadoLaboratory of Virology, Tropical Medicine Institute (IMT), University of São Paulo, São Paulo, Brazil.
Luiza GuilhermeLaboratory of Immunology, Heart Institute (InCor), Clinical Hospital, University of São Paulo, São Paulo, Brazil.
Hospital Amaral Carvalho · BRUniversidade de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hematopoietic stem cell transplantation (HSCT) is an important therapeutic option for some hematological diseases. However, patients who undergo HSCT acquire a state of immunodeficiency that causes significant mortality. Reconstitution of thymic function is needed to support the immune system. One way to measure thymic function is through T-cell receptor excision circle (TREC) quantification. TRECs are generated by T-cell receptor gene rearrangements during T-cell maturation in the thymus and represent a reliable marker for thymic output. In this study, we aimed to assess aging and malignant hematological diseases as two important factors that may influence thymic output before HSCT. We observed that patients before HSCT presented signal joint TREC (sjTREC) numbers lower than 606.55 copies/μg DNA (low values) compared with healthy individuals, with an odds ratio (OR) of 12.88 [95% confidence interval (CI): 5.26-31.53;

Indexed as

Hematopoietic Stem Cell TransplantationLymphopoiesisAdolescentAdultCase-Control StudiesFemaleGraft vs Host DiseaseHematologic NeoplasmsHematopoietic Stem CellsHumansMaleMiddle AgedReceptors, Antigen, T-CellThymus GlandT-Lymphocyte SubsetsYoung AdultReceptors, Antigen, T-Celladaptive immune systemallogeneic hematopoietic stem cell transplantationautologous hematopoietic stem cell transplantationimmune reconstitutionmalignant hematological diseasesT-cell receptor excision circlesT-cell receptor genethymopoiesis

Identifiers

PMID30245685
PMCPMC6137257
OpenAlexW2890914161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.